368 related articles for article (PubMed ID: 17338651)
1. Thrombosis in multiple myeloma.
Zangari M; Elice F; Fink L; Tricot G
Expert Rev Anticancer Ther; 2007 Mar; 7(3):307-15. PubMed ID: 17338651
[TBL] [Abstract][Full Text] [Related]
2. [Thromboembolic risk associated with use of angiogenesis inhibitors used for the treatment of cancers].
Drouet L
Pathol Biol (Paris); 2008 Jun; 56(4):195-204. PubMed ID: 18450388
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin.
Cini M; Zamagni E; Valdré L; Palareti G; Patriarca F; Tacchetti P; Legnani C; Catalano L; Masini L; Tosi P; Gozzetti A; Cavo M
Eur J Haematol; 2010 Jun; 84(6):484-92. PubMed ID: 20192986
[TBL] [Abstract][Full Text] [Related]
4. Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates.
Gieseler F
Thromb Haemost; 2008 Jun; 99(6):1001-7. PubMed ID: 18521500
[TBL] [Abstract][Full Text] [Related]
5. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
Zamagni E; Brioli A; Tacchetti P; Zannetti B; Pantani L; Cavo M
Semin Thromb Hemost; 2011 Apr; 37(3):209-19. PubMed ID: 21455855
[TBL] [Abstract][Full Text] [Related]
6. Hemostatic dysfunction in paraproteinemias and amyloidosis.
Zangari M; Elice F; Fink L; Tricot G
Semin Thromb Hemost; 2007 Jun; 33(4):339-49. PubMed ID: 17525891
[TBL] [Abstract][Full Text] [Related]
7. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Palumbo A; Cavo M; Bringhen S; Zamagni E; Romano A; Patriarca F; Rossi D; Gentilini F; Crippa C; Galli M; Nozzoli C; Ria R; Marasca R; Montefusco V; Baldini L; Elice F; Callea V; Pulini S; Carella AM; Zambello R; Benevolo G; Magarotto V; Tacchetti P; Pescosta N; Cellini C; Polloni C; Evangelista A; Caravita T; Morabito F; Offidani M; Tosi P; Boccadoro M
J Clin Oncol; 2011 Mar; 29(8):986-93. PubMed ID: 21282540
[TBL] [Abstract][Full Text] [Related]
8. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
Talamo GP; Ibrahim S; Claxton D; Tricot GJ; Fink LM; Zangari M
Blood Coagul Fibrinolysis; 2009 Jul; 20(5):337-9. PubMed ID: 19367157
[TBL] [Abstract][Full Text] [Related]
9. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone.
Klein U; Kosely F; Hillengass J; Hundemer M; Schmitt S; Neben K; Moehler T; Hegenbart U; Ho AD; Goldschmidt H
Ann Hematol; 2009 Jan; 88(1):67-71. PubMed ID: 18668241
[TBL] [Abstract][Full Text] [Related]
10. Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.
Musallam KM; Dahdaleh FS; Shamseddine AI; Taher AT
Thromb Res; 2009 Mar; 123(5):679-86. PubMed ID: 18992924
[TBL] [Abstract][Full Text] [Related]
11. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Palumbo A; Rajkumar SV; Dimopoulos MA; Richardson PG; San Miguel J; Barlogie B; Harousseau J; Zonder JA; Cavo M; Zangari M; Attal M; Belch A; Knop S; Joshua D; Sezer O; Ludwig H; Vesole D; Bladé J; Kyle R; Westin J; Weber D; Bringhen S; Niesvizky R; Waage A; von Lilienfeld-Toal M; Lonial S; Morgan GJ; Orlowski RZ; Shimizu K; Anderson KC; Boccadoro M; Durie BG; Sonneveld P; Hussein MA;
Leukemia; 2008 Feb; 22(2):414-23. PubMed ID: 18094721
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma.
Galli M; Elice F; Crippa C; Comotti B; Rodeghiero F; Barbui T
Haematologica; 2004 Sep; 89(9):1141-2. PubMed ID: 15377478
[TBL] [Abstract][Full Text] [Related]
13. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations.
Hussein MA
Thromb Haemost; 2006 Jun; 95(6):924-30. PubMed ID: 16732369
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide and thrombosis. A meta-analysis.
El Accaoui RN; Shamseddeen WA; Taher AT
Thromb Haemost; 2007 Jun; 97(6):1031-6. PubMed ID: 17549307
[TBL] [Abstract][Full Text] [Related]
15. Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis.
van Heeckeren WJ; Sanborn SL; Narayan A; Cooney MM; McCrae KR; Schmaier AH; Remick SC
Curr Opin Hematol; 2007 Sep; 14(5):468-80. PubMed ID: 17934353
[TBL] [Abstract][Full Text] [Related]
16. Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital.
Alexander M; Teoh KC; Lingaratnam S; Kirsa S; Mellor JD
Asia Pac J Clin Oncol; 2013 Jun; 9(2):169-75. PubMed ID: 22998589
[TBL] [Abstract][Full Text] [Related]
17. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.
Zangari M; Barlogie B; Anaissie E; Saghafifar F; Eddlemon P; Jacobson J; Lee CK; Thertulien R; Talamo G; Thomas T; Van Rhee F; Fassas A; Fink L; Tricot G
Br J Haematol; 2004 Sep; 126(5):715-21. PubMed ID: 15327525
[TBL] [Abstract][Full Text] [Related]
18. Update of thrombosis in multiple myeloma.
Leebeek FW
Thromb Res; 2016 Apr; 140 Suppl 1():S76-80. PubMed ID: 27067983
[TBL] [Abstract][Full Text] [Related]
19. Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis.
Uaprasert N; Voorhees PM; Mackman N; Key NS
Eur J Cancer; 2010 Jul; 46(10):1790-9. PubMed ID: 20385482
[TBL] [Abstract][Full Text] [Related]
20. Clinical studies with anticoagulants to improve survival in cancer patients.
Gerotziafas GT; Papageorgiou C; Hatmi M; Samama MM; Elalamy I
Pathophysiol Haemost Thromb; 2008; 36(3-4):204-11. PubMed ID: 19176993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
